- Recommendation ID
- Induction of remission for people with moderate ulcerative colitis: prednisolone compared with
aminosalicylates:- What is the clinical and cost effectiveness of prednisolone compared with aminosalicylates for the induction of remission for people with moderate ulcerative colitis?
- Any explanatory notes
- Why this is important:- Currently, people with moderate active ulcerative colitis most frequently receive either aminosalicylates or prednisolone as treatment, but there is no direct trial evidence comparing these treatments. Therefore people may receive treatment that is either less effective (in terms of symptom reduction or resolution, quality of life or healing of the colonic mucosa) or associated with greater side effects (especially with prednisolone). This is an important question in children, but the use of steroids is more contentious in children and there may be greater reluctance to use them because of possible effects on growth and development. People with moderate exacerbations of ulcerative colitis would be recruited and randomised to receive either prednisolone plus a bone-protecting agent or high-dose aminosalicylates. Primary end-points should be clinical remission and endoscopic remission.
Source guidance details
- Comes from guidance
- Ulcerative colitis: management
- Date issued
- June 2013
|Is this a recommendation for the use of a technology only in the context of research?||No|
|Is it a recommendation that suggests collection of data or the establishment of a register?||No|